Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes

Technology appraisal guidance
Reference number: TA47
Published: 05 September 2002
Last updated: 01 March 2010

Cost-effectiveness model: Glycoprotein Antagonists

This is the cost-effectiveness model comparing alternative management strategies for the use of Glycoprotein IIb/IIIa antagonists in non-ST-elevation acute coronary syndrome.

Cost-effectiveness model: Glycoprotein Antagonists
15 May 2002
(956.57 Kb 38 sec)

Adobe Acrobat reader required.

This page was last updated: 30 March 2010